← Leaderboards
Julia L. Marcus
Kaiser Foundation Research Institute
$6,429,395
Attributed
$8,940,946
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,940,946 · 7
By mechanism
R01$4,714,482 · 2
RF1$1,870,662 · 1
R21$958,340 · 2
R34$742,681 · 1
K01$654,781 · 1
Top collaborators
- Douglas Scott Krakower7 shared
- Jessica Gerald Young2 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- William M Vollmer$16,126,358
- Jason M Glanz$7,837,583
- Rachel Gold$17,398,894
- Frances L Lynch$8,131,690
- Benjamin Alexander White$1,660,781
Others in their field
Top investigators on “Electronic Health Record”
- Larry Arthur$206,000,000
- Lee Marshall Nadler · Dana-Farber Cancer Inst$123,638,056
- Asimah Rafi · Technical Resources Inc$95,881,052
- Daniel Ernest Ford · Johns Hopkins University$75,786,253
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$65,323,579
- Robert P Kimberly · University Of Alabama At Birmingham$64,527,475
Research focus
Electronic Health RecordHiv InfectionsCaliforniaInnovationUptakeIncidenceCaringEpidemicEconomicsHigh RiskMemberProviderAffectCostUnited States National Institutes Of HealthAdherenceRacial DiversityUnderserved PopulationFocus GroupsDiagnosisEpidemiologyHiv DiagnosisHealthcare SystemsMen Who Have Sex With Men
Grant awards (19)
Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing in Community Health Centers (PrEDICT)$1,870,662
RF1 · FY2025 · MH · contact PI
Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)$762,559
R01 · FY2025 · AI · contact PI
Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)$790,624
R01 · FY2024 · AI · contact PI
Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing in Community Health Centers (PrEDICT)$643,511
R01 · FY2024 · MH · contact PI
Over-the-Counter PrEP: Acceptability, Feasibility, and Potential Impact of Access without a Prescription (OFFSCRIPT)$489,120
R21 · FY2024 · MH · contact PI
Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)$813,488
R01 · FY2023 · AI · contact PI
Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing in Community Health Centers (PrEDICT)$807,908
R01 · FY2023 · MH · contact PI
Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)$896,392
R01 · FY2022 · AI · contact PI
EHR-Based Prediction Models to Improve PrEP Use in Community Health Centers$233,348
R34 · FY2022 · MH · contact PI
EHR-Based Prediction Models to Improve PrEP Use in Community Health Centers$229,026
R34 · FY2021 · MH · contact PI
EHR-Based Prediction Models to Improve PrEP Use in Community Health Centers$280,307
R34 · FY2020 · MH · contact PI
Population-Level Effects of Increasing PrEP Uptake on HIV and Bacterial STIs$207,597
R21 · FY2020 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$108,403
K01 · FY2020 · AI · contact PI
Population-Level Effects of Increasing PrEP Uptake on HIV and Bacterial STIs$261,623
R21 · FY2019 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$109,308
K01 · FY2019 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$144,850
K01 · FY2018 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$145,520
K01 · FY2017 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$120,178
K01 · FY2016 · AI · contact PI
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment Era$26,522
K01 · FY2016 · AI · contact PI